A Rethink for IO Biomarkers.
Predictive biomarkers of immunotherapy are growing increasingly complex-incorporating aspects of tumor-intrinsic, immune microenvironmental, and host-related biology-and several new initiatives aim to establish standards for the field to ensure consistency of commercial assays going forward.